We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $697M
1-Year Est. Return 79.73%
This Fund
S&P 500
This Quarter Est. Return
+11.82%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$252M
AUM Growth
-$117M
Cap. Flow
-$138M
Cap. Flow %
-54.92%
Top 10 Hldgs %
67.87%
Holding
57
New
9
Increased
3
Reduced
13
Closed
18

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$23.6M
2
MMS icon
Maximus
MMS
+$13.9M
3
ANNX icon
Annexon
ANNX
+$8.5M
4
RLAY icon
Relay Therapeutics
RLAY
+$7.07M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$4.66M

Top Sells

Rank Stock Value
1
TFX icon
Teleflex
TFX
+$16.8M
2
LH icon
Labcorp
LH
+$16M
3
SNN icon
Smith & Nephew
SNN
+$14.4M
4
OGN icon
Organon & Co
OGN
+$12.6M
5
GSK icon
GSK
GSK
+$12M

Sector Composition

Rank Sector Weight
1 Healthcare 78.37%
2 Industrials 5.73%
3 Consumer Staples 4.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FHTX icon
26
Foghorn Therapeutics
FHTX
$285M
$1.13M 0.45%
121,672
– –
XFOR icon
27
X4 Pharmaceuticals
XFOR
$403M
$872K 0.35%
43,450
-39,877
-48% -$832K
APRE icon
28
Aprea Therapeutics
APRE
$7.8M
$761K 0.3%
276,603
– –
AVTX icon
29
Avalo Therapeutics
AVTX
$1.01B
$679K 0.27%
71,458
– –
RAPT
30
DELISTED
RAPT Therapeutics
RAPT
$633K 0.25%
39,375
– –
BOLD
31
Boundless Bio
BOLD
$64.1M
$562K 0.22%
162,058
– –
NYXH
32
Nyxoah
NYXH
$143M
$486K 0.19%
50,839
– –
VSTM icon
33
Verastem
VSTM
$522M
$399K 0.16%
133,412
– –
MODD icon
34
Modular Medical
MODD
$11M
$272K 0.11%
4,026
-47,286
-92% -$2.55M
NXTC icon
35
NextCure
NXTC
$22.5M
$178K 0.07%
10,833
– –
HUMAW icon
36
Humacyte Inc Warrant
HUMAW
$1.4M
$89K 0.04%
49,998
– –
TERN
37
DELISTED
Terns Pharmaceuticals
TERN
$83.4K 0.03%
+10,000
New +$82.3K
RCKTW icon
38
Rocket Pharmaceuticals Warrant
RCKTW
$192K
$28.9K 0.01%
400,000
– –
CMAXW
39
DELISTED
CareMax, Inc. Warrant
CMAXW
$108 ﹤0.01%
12,808
– –
ABT icon
40
Abbott
ABT
$181B
– –
-89,500
Closed -$9.3M
ANIP icon
41
ANI Pharmaceuticals
ANIP
$1.83B
– –
-71,740
Closed -$4.57M
APGE icon
42
Apogee Therapeutics
APGE
$10.1B
– –
-78,000
Closed -$3.07M
ARQT icon
43
Arcutis Biotherapeutics
ARQT
$3.35B
– –
-159,626
Closed -$1.48M
BBIO icon
44
BridgeBio Pharma
BBIO
$16.2B
– –
-125,174
Closed -$3.17M
BLCO icon
45
Bausch + Lomb
BLCO
$5.95B
– –
-302,710
Closed -$4.4M
CRBP icon
46
Corbus Pharmaceuticals
CRBP
$179M
– –
-225,165
Closed -$10.2M
GSK icon
47
GSK
GSK
$104B
– –
-312,000
Closed -$12M
INSM icon
48
PUT
Insmed
INSM
$21.7B
– –
-1,362,700
Closed -$91.3M
OGN icon
49
Organon & Co
OGN
$3.56B
– –
-608,096
Closed -$12.6M
PCRX icon
50
PUT
Pacira BioSciences
PCRX
$1.03B
– –
-455,500
Closed -$13M
1
2
3

Similar funds

GUB
Golden Unicorn BVI Road Town $697M AUM 55.92% 1-Year Est. Return
KLI
Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return
JA
JLB & Associates Plymouth, Michigan $696M AUM 17.86% 1-Year Est. Return
WIC
Wilkins Investment Counsel Boston, Massachusetts $698M AUM 17.36% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $696M AUM 18.07% 1-Year Est. Return
TCM
Tensile Capital Management Larkspur, California $698M AUM 2.4% 1-Year Est. Return
CA
Calton & Associates Tampa, Florida $696M AUM 18.3% 1-Year Est. Return
SAM
Silverback Asset Management Chapel Hill, North Carolina $699M AUM 72.42% 1-Year Est. Return

Sio Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Sio Capital Management held 57 positions worth $252M, down 32% from $370M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Sio Capital Management withdrew a net $138M in Q3 2024, closing 18 positions and reducing 13 holdings. Its most notable exit was Smith & Nephew, an estimated $14.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 69% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Sio Capital Management opened a new position in Teva Pharmaceuticals worth $24.3M.

  • Sio Capital Management's largest Q3 2024 buy was Teva Pharmaceuticals: 1,349,274 shares worth $24.3M.
  • Sio Capital Management added most to Compass Pathways in Q3 2024, an estimated $4.38M increase.
  • Sio Capital Management's biggest Q3 2024 reduction was Teleflex, cutting an estimated $16.8M.
  • Sio Capital Management fully exited Smith & Nephew in Q3 2024, selling an estimated $14.4M.
  • Sio Capital Management's ten largest holdings make up 68% of its $252M portfolio in Q3 2024.
  • Sio Capital Management opened 9 new positions and closed 18 in Q3 2024.
  • Sio Capital Management's portfolio value fell 32% quarter-over-quarter to $252M.

Based on Sio Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.